Non-agonistic bivalent antibodies that promote c-MET degradation and inhibit tumor growth and others specific for tumor related c-MET.

The c-MET receptor has a function in many human cancers and is a proven therapeutic target. Generating antagonistic or therapeutic monoclonal antibodies (mAbs) targeting c-MET has been difficult because bivalent, intact anti-Met antibodies frequently display agonistic activity, necessitating the use...

Full description

Bibliographic Details
Main Authors: Sameer A Greenall, Ermanno Gherardi, Zhanqi Liu, Jacqueline F Donoghue, Angela A Vitali, Qian Li, Roger Murphy, Luisa Iamele, Andrew M Scott, Terrance G Johns
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2012-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC3325269?pdf=render